Background/Aims: The objective was to evaluate endocrine complications in survivors of hematopoietic stem cell transplantation (HSCT) performed during childhood. Methods: Endocrine dysfunction and metabolic syndrome parameters were assessed by chart review of 178 childhood HSCT survivors (median age at evaluation, 15.5 [range: 3.8–29.8] years; median follow-up, 8.5 [range: 2–23.4] years). Results: The following statistically significant associations were identified (p < 0.05 for all): growth hormone deficiency (17.4%) was associated with cranial/craniospinal irradiation, total body irradiation (TBI), allogeneic HSCT, and longer follow-up. Short adult stature (23.3% of patients who had attained adult height) was associated with cranial/craniospinal irradiation and, in females, with younger age at HSCT. Primary gonadal failure was more prevalent in females (52.6 vs. 24.1%), and was associated with TBI in males and with a primary diagnosis of hematological malignancy in females. Hypothyroidism (25.2%) was associated with previous neck/mediastinal irradiation. Metabolic disturbances included obesity (3.9%), type 2 diabetes (2.2%), impaired glucose tolerance (2.8%), and dyslipidemia (18.5%). Dyslipidemia was associated with a primary diagnosis of hematological malignancy, TBI, and a positive family history of dyslipidemia. Endocrine dysfunction was less frequent in patients who had received fludarabine. Conclusions: Patients after HSCT require long-term surveillance for the detection of endocrine and metabolic disorders. Nonmyeloablative conditioning regimens may reduce the incidence of these complications.

Keywords:
Endocrine dysfunction after bone marrow transplant, Metabolic syndrome, Children and adolescents
1.
Andersson BS, de Lima M, Thall PF, Madden T, Russell JA, Champlin RE: Reduced-toxicity conditioning therapy with allogeneic stem cell transplantation for acute leukemia. Curr Opin Oncol 2009; 21(suppl 1):S11–S15.
2.
Leiper AD: Non-endocrine late complications of bone marrow transplantation in childhood: part I. Br J Haematol 2002; 118: 3–43.
3.
Baker KS, Chow E, Steinberger J: Metabolic syndrome and cardiovascular risk in survivors after hematopoietic cell transplantation. Bone Marrow Transplant 2012; 47: 619–625.
4.
Shalitin S, Phillip M, Stein J, Goshen Y, Carmi D, Yaniv I: Endocrine dysfunction and parameters of the metabolic syndrome after bone marrow transplantation during childhood and adolescence. Bone Marrow Transplant 2006; 37: 1109–1117.
5.
Mertens AC, Liu Q, Neglia JP, Wasilewski K, Leisenring W, Armstrong GT, Robison LL, Yasui Y: Cause-specific late mortality among 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. J Natl Cancer Inst 2008; 100: 1368–1379.
6.
Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, Apperley J, Slavin S, Pasquini M, Sandmaier BM, Barrett J, Blaise D, Lowski R, Horowitz M: Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 2009; 15: 1628–1633.
7.
Marshall WA, Tanner JM: Variations in the pattern of pubertal changes in boys. Arch Dis Child 1970; 45: 12–23.
8.
Marshall WA, Tanner JM: Variations in the pattern of pubertal changes in girls. Arch Dis Child 1969; 44: 291–303.
9.
Kuczmarski RJ, Ogden CL, Grummer-Strawn LM: CDC growth charts: United States. Adv Data 2000; 8: 1–27.
10.
Hermanussen M, Cole TJ: The calculation of target height reconsideration. Horm Res 2003; 59: 180–183.
11.
National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents: The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 2004; 114(2 suppl 4th Report):555–576.
12.
Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560–2572.
13.
Styne DM: The testes: disorders of sexual differentiation and puberty in the male; in Sperling MA (ed): Pediatric Endocrinology, ed 2. Philadelphia, Elsevier Science, 2002, p 599.
14.
Rosenfield R: Puberty in the female and its disorders; in Sperling MA (ed): Pediatric Endocrinology, ed 2. Philadelphia, Elsevier Science, 2002, p 494.
15.
Daniels SR, Greer FR; Committee on Nutrition: Lipid screening and cardiovascular health in childhood. Pediatrics 2008; 122: 198–208.
16.
National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143–3421.
17.
Brennan BMD, Shalet SM: Endocrine late effects after bone marrow transplant. Br J Haematol 2002; 118: 58–66.
18.
Faraci M, Barra S, Cohen A, Lanino E, Grisolia F, Miano M, Foppiano F, Sacco O, Cabria M, De Marco R, Stella G, Dallorso S, Bagnasco F, Vitale V, Dini G, Haupt R: Very late nonfatal consequences of fractionated TBI in children undergoing bone marrow transplant. Int J Radiat Oncol Biol Phys 2005; 63: 1568–1575.
19.
Perkins JL, Kunin-Batson AS, Youngren NM, Ness KK, Ulrich KJ, Hansen MJ, Petryk A, Steinberger J, Anderson FS, Baker KS: Long-term follow-up of children who underwent hematopoietic cell transplant (HCT) for AML or ALL at less than 3 years of age. Pediatr Blood Cancer 2007; 49: 958–963.
20.
Ferry C, Gemayael G, Rocha V, Labopin M, Esperou H, Robin M, de Latour RP, Ribaud P, Devergie A, Leblanc T, Gluckman E, Baruchel A, Socié G: Long-term outcomes after allogeneic stem cell transplantation of children with haematological malignancies. Bone Marrow Transplant 2007; 40: 219–224.
21.
Baker K, Ness K, Weisdorf D, Francisco L, Sun C, Forman S, Bhatia S: Late effects in survivors of acute leukemia treated with hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study. Leukemia 2010; 24: 2039–2047.
22.
Giorgiani G, Bozzola M, Locatelli F, Picco P, Zecca M, Cisternino M, Dallorso S, Bonetti F, Dini G, Borrone C, et al: Role of busulfan and total body irradiation on growth of prepubertal children receiving bone marrow transplantation and results of treatment with recombinant human growth hormone. Blood 1995; 86: 825–831.
23.
Sanders J, Guthrie K, Hoffmeister P, Woolfrey A, Carpenter P, Appelbaum F: Final adult height of patients who received hematopoietic cell transplantation in childhood. Blood 2005; 105: 1348–1354.
24.
Cohen A, Rovelli A, Bakker B, Uderzo C, van Lint M, Esperou H, Gaiero A, Leiper AD, Dopfer R, Cahn JY, Merlo F, Kolb HJ, Socié G: Final height of patients who underwent bone marrow transplantation for hematological disorders during childhood: a study by the Working Party for Late Effects-EBMT. Blood 1999; 93: 4109–4115.
25.
Bernard F, Bordigoni P, Simeoni MC, Barlogis V, Contet A, Loundou A, Thuret I, Leheup B, Chambost H, Play B, Auquier P, Michel G: Height growth during adolescence and final height after haematopoietic SCT for childhood acute leukaemia: the impact of a conditioning regimen with BU or TBI. Bone Marrow Transplant 2009; 43: 637–642.
26.
Leung W, Ahn H, Rose SR, Phipps S, Smith T, Gan K, O’Connor M, Hale GA, Kasow KA, Barfield RC, Madden RM, Pui CH: A prospective cohort study of late sequelae of pediatric allogeneic hematopoietic stem cell transplantation. Medicine (Baltimore) 2007; 86: 215–224.
27.
Schmiegelow M, Lassen S, Poulsen HS, Feldt-Rasmussen U, Schmiegelow K, Hertz H Müller J: Cranial radiotherapy of childhood brain tumors: growth hormone deficiency and its relation to the biological effective dose of irradiation in a large population-based study. Clin Endocrinol 2000; 53: 191–197.
28.
Isfan F, Kanold J, Merlin E, Contet A, Sirvent N, Rochette E, Poiree M, Terral D, Carla-Malpuech H, Reynaud R, Pereira B, Chastagner P, Simeoni MC, Auquier P, Michel G, Deméocq F: Growth hormone treatment impact on growth rate and final height of patients who received HSCT with TBI or/and cranial irradiation in childhood: a report from the French Leukaemia Long-Term Follow-Up Study (LEA). Bone Marrow Transplant 2012; 47: 684–693.
29.
Teinturier C, Hartmann O, Valteau-Couanet D, Benhamou E, Bougneres PF: Ovarian function after autologous bone marrow transplantation in childhood: high-dose busulfan is a major cause of ovarian failure. Bone Marrow Transplant 1998; 22: 989–994.
30.
Jadoul P, Anckaert E, Dewandeleer A, Steffens M, Dolmans MM, Vermylen C, Smitz J, Donnez J, Maiter D: Clinical and biologic evaluation of ovarian function in women treated by bone marrow transplantation for various indications during childhood or adolescence. Fertil Steril 2011; 96: 126–133.e3.
31.
Wallace WH, Thomson AB, Kelsey TW: The radiosensitivity of the human oocyte. Hum Reprod 2003; 18: 117–121.
32.
Sklar CA, Kim TH, Ramsay NK: Testicular function following bone marrow transplantation performed during or after puberty. Cancer 1984; 53: 1498–1501.
33.
Borgstrom B, Bolme P: Thyroid function in children after allogeneic bone marrow transplantation. Bone Marrow Transplant 1994; 13: 59–64.
34.
Ishiguro H, Yasuda Y, Tomita Y, Shinagawa T, Shimizu T, Morimoto T, Hattori K, Matsumoto M, Inoue H, Yabe H, Yabe M, Shinohara O, Kato S: Long-term follow-up of thyroid function in patients who received bone marrow transplantation during childhood and adolescence. J Clin Endocrinol Metab 2004; 89: 5981–5986.
35.
Sklar C, Whitton J, Mertens A, Stovall M, Green D, Marina N, Greffe B, Wolden S, Robison L: Abnormalities of the thyroid in survivors of Hodgkin’s disease: data from the Childhood Cancer Survivors Study. J Clin Endocrinol Metab 2000; 85: 3227–3232.
36.
Pacini F, Vorontsova T, Demidchik EP, Molinaro E, Agate L, Cristina Romei C, Shavrova E, Cherstvoy ED, Ivashkevitch Y, Kuchinskaya E, Schlumberger M, Ronga G, Filesi M, Pinchera A: Post-Chernobyl thyroid carcinoma in Belarus children and adolescents: comparison with naturally occurring thyroid carcinoma in Italy and France. J Clin Endocrinol Metab 1997; 82: 3653–3569.
37.
Socie G, Curtis RE, Deeg HJ, Sobocinski KA, Filipovich AH, Travis LB, Sullivan KM, Rowlings PA, Kingma DW, Banks PM, Travis WD, Witherspoon RP, Sanders J, Jaffe ES, Horowitz MM: New malignant diseases after allogeneic bone marrow transplantation for childhood acute leukemia. J Clin Oncol 2000; 18: 348–357.
38.
Chow EJ, Anderson L, Baker KS, Bhatia S, Guilcher GM, Huang JT, Pelletier W, Perkins JL, Rivard LS, Schechter T, Shah AJ, Wilson KD, Wong K, Grewal SS, Armenian SH, Meacham LR, Mulrooney DA, Castellino SM: Late effects surveillance recommendations among survivors of childhood hematopoietic cell transplantation: a children’s oncology group report. Biol Blood Marrow Transplant 2016; 22: 782–795.
39.
Taskinen M, Saarinen-Pinkala UM, Hovi L, Lipsanen-Nyman M: Impaired glucose tolerance and dyslipidemia as late effects after bone-marrow transplantation in childhood. Lancet 2000; 16: 993–997.
40.
Rabinowicz M: Overweight and obesity: review of the situation in Israel. http://www.knesset.gov.il/mmm/data/pdf/m02303.pdf (accessed June 18, 2009).
41.
Bizzarri C, Pinto RM, Ciccone S, Brescia LP, Locatelli F, Cappa M: Early and progressive insulin resistance in young, non-obese cancer survivors treated with hematopoietic stem cell transplantation. Pediatr Blood Cancer 2015; 62: 1650–1655.
42.
Surapolchai P, Hongeng S, Mahachoklertwattana P, Pakakasama S, Winaichatsak A, Wisanuyothin N, Pasomsub E, Mahasirimongkol S, Sirachainan N: Impaired glucose tolerance and insulin resistance in survivors of childhood acute lymphoblastic leukemia: prevalence and risk factors. J Pediatr Hematol Oncol 2010; 32: 383–389.
43.
Mayson SE, Parker VE, Schutta MH, Semple RK, Rickels MR: Severe insulin resistance and hypertriglyceridemia after childhood total body irradiation. Endocr Pract 2013; 19: 51–58.
44.
Mostoufi-Moab S, Magland J, Isaacoff EJ, Sun W, Rajapakse CS, Zemel B, Wehrli F, Shekdar K, Baker J, Long J, Leonard MB: Adverse fat depots and marrow adiposity are associated with skeletal deficits and insulin resistance in long-term survivors of pediatric hematopoietic stem cell transplantation. J Bone Miner Res 2015; 30: 1657–1666.
45.
Bakker B, Oostdijk W, Bresters D, Walenkamp MJ, Vossen JM, Wit JM: Disturbances of growth and endocrine function after busulphan-based conditioning for haematopoietic stem cell transplantation during infancy and childhood. Bone Marrow Transplant 2004; 33: 1049–1056.
46.
Jung MH, Cho KS, Lee JW, Chung NG, Cho B, Suh BK, Kim HK, Lee BC: Endocrine complications after hematopoietic stem cell transplantation during childhood and adolescence. J Korean Med Sci 2009; 24: 1071–1077.
47.
Wilhelmsson M, Vatanen A, Borgström B, Gustafsson B, Taskinen M, Saarinen-Pihkala UM, Winiarski J, Jahnukainen K: Adverse health events and late mortality after pediatric allogeneic hematopoietic SCT-two decades of longitudinal follow-up. Bone Marrow Transplant 2015; 50: 850–857.
48.
Armenian SH, Sun CL, Kawashima T, Arora M, Leisenring W, Sklar CA, Baker KS, Francisco L, Teh JB, Mills G, Wong FL, Rosenthal J, Diller LR, Hudson MM, Oeffinger KC, Forman SJ, Robison LL, Bhatia S: Long-term health-related outcomes in survivors of childhood cancer treated with HSCT versus conventional therapy: a report from the Bone Marrow Transplant Survivor Study (BMTSS) and Childhood Cancer Survivor Study (CCSS). Blood 2011; 118: 1413–1420.
49.
Bresters D, van Gils IC, Kollen WJ, Ball LM, Oostdijk W, van der Bom JG, Egeler RM: High burden of late effects after haematopoietic stem cell transplantation in childhood: a single-centre study. Bone Marrow Transplant 2010; 45: 79–85.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.